MedMira Inc V.MIR

PERFECT PRODUCT

[beercan]

Attention Business/Medical Editors: Reveal(TM) Rapid HIV-1 Antibody Test indicates 100% sensitivity in independent clinical study HALIFAX, May 5 /CNW/ - MedMira Inc. (MedMira) (TSX Venture: MIR) announced today that Brown University (Providence, Rhode Island) in conjunction with Walter Reed Army Institute of Research (Rockville, Maryland) has completed an independent sensitivity study of MedMira's Reveal(TM) Rapid HIV-1 Antibody Test. The results of this study indicated a sensitivity of 100% to all specimens collected from the one hundred HIV infected participants recruited from the Immunology Clinic of The Miriam Hospital. The Reveal(TM) Rapid HIV-1 Antibody Test has very recently received a Pre-Market Approval from the United States Food and Drug Administration. "The Reveal(TM) Rapid HIV-1 Antibody Test is sensitive and easy to perform," said Dr. Michele Lally, the lead investigator at Brown University. "I believe that this test would be extremely useful to clinical laboratory settings across the United States." "We are very pleased to have the opportunity to participate in this study," said Stephen Sham, Chairman and CEO of MedMira. "The results of this study have once again affirmed the superior performance of our Reveal(TM) Rapid HIV-1 Antibody Test. A rapid HIV test with a long 12-month shelf-life at room temperature which provides results within 3 minutes, regardless of HIV status of the testing specimen, will certainly be an excellent tool to assist in fighting the recent uprising HIV cases in United States." MedMira (www.medmira.com) is a commercial biotechnology company that develops, manufactures and markets qualitative, in vitro diagnostic tests for the detection of antibodies to certain diseases, such as HIV, in human serum, plasma or whole blood. MedMira's Reveal(TM) and MiraWell(TM) Rapid HIV Tests have recently been approved by the United States FDA and SDA in the People's Republic of China, respectively. All of MedMira's diagnostic tests are based on the same flow-through technology platform thus facilitating the development of future products. MedMira's technology provides a quick (under 3 minutes), accurate, portable, safe and cost-effective alternative to conventional laboratory testing. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. %SEDAR: 00013053E -30- For further information: PLEASE CONTACT: Dr. James Smith: [phone] or e-mail: [e-mail] INC. has 50 releases in this database. --------------------------------------------------------------------------------